Skip to main content

Articles

Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy

Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy

By Phoebe Starr

TOP - August 2018, Vol 11, No 2

A new study presented at the 2018 American Association for Cancer Research meeting suggests that HER2 mutations can be acquired during metastatic cancer and their development represents a previously unreported mechanism of resistance to treatment. Read More ›

Using Cancer Drugs Wisely to Control Costs: Targeted Therapies May Hold the Key

Using Cancer Drugs Wisely to Control Costs: Targeted Therapies May Hold the Key

By Gail Thompson

TOP - August 2018, Vol 11, No 2

“It is time for us to bury the concept of maximum-tolerated dose in the world of targeted therapy,” according to Allen S. Lichter, MD, FASCO.

FDA Taking Steps to Promote Generic Drug Competition and Improve Patient Access to Therapies

FDA Taking Steps to Promote Generic Drug Competition and Improve Patient Access to Therapies

By Eileen Koutnik-Fotopoulos

Healthcare Policy

TOP - August 2018, Vol 11, No 2

While the industry does its part to improve the quality and completeness of applications, the FDA is taking action to enhance the efficiency of its review process.

Eileen Koutnik-Fotopoulos

Noteworthy Numbers: Non-Hodgkin Lymphoma

Noteworthy Numbers

TOP - August 2018, Vol 11, No 2

Patients with indolent subtypes of NHL have a relatively good prognosis with a median survival as long as 20 years, although these subtypes of the disease are typically not curable in advanced stages.

An Assessment of PARP Inhibitors in the Treatment of Recurrent Ovarian Cancer

An Assessment of PARP Inhibitors in the Treatment of Recurrent Ovarian Cancer

By Penny Daugherty, RN, MS, OCN, ONN-CG

Rx Profiler The PARP Inhibitor Rucaparib in the Maintenance Therapy of Recurrent Ovarian Carcinoma: Highlights from the ARIEL3 Clinical Trial

Ovarian cancer is an avaricious tumor that can extend throughout the entire abdominal cavity. It is one of the most difficult diseases to diagnose and the most lethal gynecologic malignancy, being the fifth leading cause of cancer death in women in the United States.

Penny Daugherty, RN, MS, OCN, ONN-CG

An Assessment of PARP Inhibitors in the Treatment of Recurrent Ovarian Cancer

An Assessment of PARP Inhibitors in the Treatment of Recurrent Ovarian Cancer

By Penny Daugherty, RN, MS, OCN, ONN-CG

Rx Profiler - The PARP Inhibitor Rucaparib in the Maintenance Therapy of Recurrent Ovarian Carcinoma: Highlights from the ARIEL3 Clinical Trial

Ovarian cancer is an avaricious tumor that can extend throughout the entire abdominal cavity. It is one of the most difficult diseases to diagnose and the most lethal gynecologic malignancy, being the fifth leading cause of cancer death in women in the United States.

Penny Daugherty, RN, MS, OCN, ONN-CG

What the Next Generation of Cancer Biomarkers May Involve

What the Next Generation of Cancer Biomarkers May Involve

By Sanjiv Agarwala, MD

Video, ASCO Highlights

Dr Sanjiv Agarwala predicts that the cancer biomarkers of the future may be “mobile biomarkers,” meaning measures of the tumor microenvironment or immune response that change with therapy and may be able to determine treatment efficacy. Read More ›

Sanjiv Agarwala, MD

How MSI and TMB Factor into Current Biomarker Testing Panels

How MSI and TMB Factor into Current Biomarker Testing Panels

By Sanjiv Agarwala, MD

Video, ASCO Highlights

Dr Sanjiv Agarwala discusses the usefulness of MSI and TMB as novel biomarkers for various cancer types. His argument is that the first FDA approval of a therapy based on MSI rather than tumor type makes this biomarker useful, but TMB is not yet ready for “prime time.” Read More ›

Sanjiv Agarwala, MD

Best Practices in How Oncologists and Pathologists Can Work Together to Optimize Biomarker Testing for their Patients with Cancer

Best Practices in How Oncologists and Pathologists Can Work Together to Optimize Biomarker Testing for their Patients with Cancer

By Sanjiv Agarwala, MD

Video, ASCO Highlights

Dr Sanjiv Agarwala describes best practices developed at St. Luke’s Cancer Center, where a committee has been formed in which clinicians and pathologists meet to reach consensus on reflex testing of molecular biomarkers, as well as the value of biomarker testing in enhancing patient care. Read More ›

Sanjiv Agarwala, MD

Biomarker Data in Melanoma Presented at ASCO 2018 Are Largely Extensions of Previous Studies Rather Than New Discoveries

Biomarker Data in Melanoma Presented at ASCO 2018 Are Largely Extensions of Previous Studies Rather Than New Discoveries

By Sanjiv Agarwala, MD

Video, ASCO Highlights

Dr Sanjiv Agarwala argues that much of the biomarker data in melanoma presented at ASCO 2018 are around the value of PD-L1 testing; however, even PD-L1–negative melanoma patients seem to respond to anti–PD-1 therapy, although some studies suggest PD-L1–negative patients may be better candidates for combination immunotherapy. Read More ›

Sanjiv Agarwala, MD

Page 102 of 288